Clinica Doctor Balcangiu-Stroescu

The role of diabetic neuropathy in the development of erectile dysfunction

The role of diabetic neuropathy in the development of erectile dysfunction
Useful information
April 13, 2026Valentin Iordache

Introduction

Diabetic neuropathy is one of the most important chronic complications of diabetes and a major factor involved in the development of erectile dysfunction.

Often, patients are not aware that sexual problems are caused by nerve damage.

What is diabetic neuropathy?

Diabetic neuropathy represents progressive nerve damage due to:

  • elevated blood glucose levels over a long period (chronic hyperglycemia)
  • oxidative stress
  • inflammation

This can affect:

  • peripheral nerves
  • autonomic nerves

The role of the nervous system in erection

Erection is a complex process controlled by:

  • brain
  • spinal cord
  • peripheral nerves

➡️ Any nervous system dysfunction directly affects this mechanism.

How does neuropathy cause erectile dysfunction?

1. Autonomic nerve damage

  • reduction of signals to penile vessels
  • decreased vasodilation

2. Sensory nerve damage

  • decreased sensitivity
  • diminished sexual stimulus

3. Delayed erectile response

  • erection occurs with difficulty or not at all

Signs suggestive of neuropathy

  • tingling or numbness in the feet or hands
  • decreased sensitivity
  • sensation of "coldness" in the extremities
  • persistent erectile dysfunction

Why do standard treatments sometimes not work?

In neuropathy:

  • the problem is not purely vascular
  • response to medications may be reduced

👉 Therefore, a comprehensive approach is needed.

Can it be treated?

  • strict glycemic control
  • neuropathy treatment
  • adapted urological therapies

👉 In early stages, progression can be slowed.

Conclusion

Diabetic neuropathy is a major cause of erectile dysfunction and explains why treatment must be personalized and multidisciplinary.

Also Read

Related Articles

A single injection for cholesterol — from dreams to first human results
Useful information

A single injection for cholesterol — from dreams to first human results

A Phase 1 trial published in the New England Journal of Medicine (November 2025) brings remarkable results: a single infusion of CTX310, a CRISPR-Cas9 therapy developed by Cleveland Clinic and CRISPR Therapeutics, reduced LDL cholesterol by up to 49% and triglycerides by up to 55% in patients with refractory dyslipidemia — without serious adverse events. The mechanism is unique: instead of blocking a protein or interfering with its mRNA, CTX310 permanently edits the ANGPTL3 gene in hepatic cells, mimicking a natural mutation associated with reduced cardiovascular risk throughout life. The therapy is currently in Phase 1b clinical stage, with updates expected in the second half of 2026. It is not approved and does not replace current treatments. Read the full article for clinical context, comparison with statins and PCSK9 inhibitors, and what these data mean for patients. Medical Disclaimer This article presents results from a Phase 1 clinical trial in an early-stage research phase. The therapy described is not approved and is not available as standard treatment. The information is for educational purposes only. Consult your physician for any medical decision.

June 1, 2026Andra-Elena Balcangiu-Stroescu

Ready to schedule?

Book an appointment online or call us directly.

+40 747 777 107